Slide 2
Forward-looking statements and Disclaimer
This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding: the potential for mRNA as a
new class of medicines; the potential of Moderna’s mRNA-LNP platform; Moderna’s ability to build its mRNA platform and expand its clinical applications; Moderna’s ability to effectively utilize artificial
intelligence in the development of mRNA medicines; Moderna’s ability to optimize the parameters required for LNP engineering and to develop proprietary LNPs for different delivery goals; Moderna’s
collaborations with Vertex, including to develop an inhalable LNP; the potential for inhaled delivery of mRNA to address a range of unmet medical needs; the ability to improve vaccine stability by
understanding mRNA inactivation pathways; anticipated timing for an IND filing and clinical development of Moderna’s CFTR mRNA program in collaboration with Vertex; Moderna’s manufacturing platform
and ability to produce a robust and consistent product with a predictable stability profile; the effects of mRNA vaccination on pregnancy and fertility; the ability to use IS/ID models to predict neutralizing
antibody responses across various doses and predict a priori immunogenic responses in various age groups; and the biodistribution and safety of Moderna’s intramuscular vaccine LNPs. In some cases,
forward-looking statements can be identified by terminology such as “will,” “may,” “should,” “could,” “expects,” “intends,” “plans,” “aims,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “continue,”
or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. The forward-looking statements in this presentation are neither promises nor
guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond
Moderna’s control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include, among
others, those risks and uncertainties described under the heading “Risk Factors” in Moderna’s most recent Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) and in
subsequent filings made by Moderna with the SEC, which are available on the SEC’s website at www.sec.gov. Except as required by law, Moderna disclaims any intention or responsibility for updating or
revising any forward-looking statements contained in this presentation in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna’s current
expectations and speak only as of the date of this presentation.
© 2022 M oderna
